Market Place
Sourcing Support
Arrowhead Pharmaceuticals to Participate in June 2026 Conferences
02 Jun 2026 //
BUSINESSWIRE
Arrowhead Presents ARO-INHBE Obesity and MASH Data at EASL
27 May 2026 //
BUSINESSWIRE
Arrowhead Presents Positive Cardiometabolic Data at EAS Congress
26 May 2026 //
PHARMIWEB
Arrowhead Pharma Reports Fiscal 2026 Second Quarter Results
07 May 2026 //
PHARMIWEB
Madrigal Acquires Arrowhead`s MASH siRNA for Up to $1B
06 May 2026 //
BIOSPACE
Arrowhead Pharmaceuticals to Join Upcoming May 2026 Events
04 May 2026 //
PHARMIWEB
Arrowhead Gets TGA Approval for Plozasiran in FCS in Australia
01 May 2026 //
FIRSTWORD PHARMA
EU Backs Arrowhead’s REDEMPLO for Rare Lipid Disorder
24 Apr 2026 //
BUSINESSWIRE
Arrowhead Pharma To Webcast Q2 Fiscal 2026 Results
20 Apr 2026 //
PHARMIWEB
Arrowhead Pharma Unveils Plozasiran Data On Hypertriglyceridemia
28 Mar 2026 //
PHARMIWEB
Sarepta Overcomes Gene Therapy Setback With Early RNA Therapy
26 Mar 2026 //
BIOSPACE
Sarepta`s Big Bet On Arrowhead`s Sirna Assets Yields Early Data
25 Mar 2026 //
FIERCE BIOTECH
Revolution, Ascendis Seen As Top Buyout Targets In Biopharma
19 Mar 2026 //
BIOSPACE
Arrowhead to Participate in Upcoming March 2026 Events
24 Feb 2026 //
BUSINESSWIRE
Arrowhead Pharma Reveals Q1 2026 Financial Report
05 Feb 2026 //
BUSINESSWIRE
Arrowhead Pharma Starts Phase 1/2A Trial For ARO-DIMER-PA
27 Jan 2026 //
BUSINESSWIRE
Arrowhead Pharma To Webcast Q1 Fiscal 2026 Results
20 Jan 2026 //
BUSINESSWIRE
Arrowhead Pharma Gets NMPA Nod For REDEMPLO In China For FCS
07 Jan 2026 //
BUSINESSWIRE
Arrowhead Pharma Reports Weight Loss in Obesity RNAi Trial
06 Jan 2026 //
BUSINESSWIRE
Health Canada Approves Arrowhead`s REDEMPLO for Adult FCS
05 Jan 2026 //
BUSINESSWIRE
Arrowhead Pharmaceuticals`s Redemplo Approved in Canada
02 Jan 2026 //
HEALTH CANADA
Arrowhead Pharma To Join January 2026 Conferences
23 Dec 2025 //
BUSINESSWIRE
Arrowhead Pharma Issues Inducement Grants Under Nasdaq 5635(c)(4)
15 Dec 2025 //
BUSINESSWIRE
Arrowhead Pharma Launches Phase 1/2a ARO-MAPT Trial in
08 Dec 2025 //
BUSINESSWIRE
Arrowhead Pharma Granted Breakthrough Designation For Plozasiran
02 Dec 2025 //
BUSINESSWIRE
Arrowhead Pharma To Join December 2025 Conferences
01 Dec 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
25 Nov 2025 //
BUSINESSWIRE
Arrowhead Pharma Receives $200M Milestone Payment From Sarepta
24 Nov 2025 //
BUSINESSWIRE
Arrowhead Pharma’s Redemplo Receives Approval in US
18 Nov 2025 //
FDA
FDA Approves Arrowhead`s Genetic Disorder Drug
18 Nov 2025 //
FDA
Arrowhead Pharmaceuticals To Webcast Fiscal 2025 Year-End Results
06 Nov 2025 //
BUSINESSWIRE
Arrowhead Pharma To Join November 2025 Conferences
04 Nov 2025 //
BUSINESSWIRE
Arrowhead Pharma Discloses Inducement Grants Per Nasdaq LR
28 Oct 2025 //
BUSINESSWIRE
Arrowhead Pharma Finalizes Collaboration Deal with Novartis
21 Oct 2025 //
BUSINESSWIRE
Arrowhead Files CTA For ARO-DIMER-PA In Mixed Hyperlipidemia
07 Oct 2025 //
PHARMIWEB
Ionis, Arrowhead in Patent Lawsuits Over Genetic Disorder Drug
11 Sep 2025 //
REUTERS
Arrowhead Seeks Clearance for Ph 1/2a ARO-MAPT Alzheimer`s Study
10 Sep 2025 //
PHARMAWEB
Arrowhead, Novartis in Up to $2B Deal for Neuromuscular Therapy
03 Sep 2025 //
REUTERS
Arrowhead Pharma to Join September 2025 Conferences
27 Aug 2025 //
BUSINESSWIRE
Sarepta Sells 9M Arrowhead Shares for $174M
13 Aug 2025 //
FIERCE BIOTECH
Arrowhead Redeems $50M Stock, Gets $50M Sarepta Milestone
13 Aug 2025 //
BUSINESSWIRE
Sarepta Advances siRNA Collaboration, Sells Arrowhead Equity
13 Aug 2025 //
BUSINESSWIRE
Arrowhead Emerges as RNAi Knight Amid Sarepta `Downdraft`
12 Aug 2025 //
BIOSPACE
Arrowhead Pharmaceuticals` Fiscal 2025 Q3 Results Released
07 Aug 2025 //
BUSINESSWIRE
Sanofi pens $395M China pact for Arrowhead Metabolic med
02 Aug 2025 //
PRESS RELEASE
Arrowhead Hits $100M Milestone, Awaits Sarepta Payment
28 Jul 2025 //
FIERCE BIOTECH
Arrowhead Reports Inducement Grants under NASDAQ LR 5635(c)(4)
24 Jul 2025 //
BUSINESSWIRE
Arrowhead Reassures investors about pact with troubled Sarepta
24 Jul 2025 //
PRESS RELEASE
Arrowhead Pharmaceuticals to Webcast Fiscal Q3 2025 Results
21 Jul 2025 //
BUSINESSWIRE
Arrowhead Starts Phase 3 YOSEMITE Study of Zodasiran
08 Jul 2025 //
BUSINESSWIRE
Arrowhead Completes Enrollment in Three Plozasiran Trials
23 Jun 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Begins Study of ARO-ALK7 for Obesity
02 Jun 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals in June 2025 Investor Conferences
29 May 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports Q2 2025 Results
12 May 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Join May 2025 Investor Conferences
07 May 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Webcast Q2 Fiscal 2025 Results
30 Apr 2025 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Names Daniel Apel CFO
15 Apr 2025 //
BUSINESSWIRE
Arrowhead Reports Inducement Grants under NASDAQ LR 5635(c)(4)
04 Apr 2025 //
BUSINESSWIRE
Arrowhead Reports Topline Ph1/2 ARO-C3 Data In IgA Nephropathy
10 Mar 2025 //
BUSINESSWIRE
Arrowhead Showcases 2RNAi Candidates For Obesity, Metabolic Disease
06 Mar 2025 //
BUSINESSWIRE
